Antithrombotic and thrombolytic therapy for ischemic stroke.

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Antithrombotic and thrombolytic therapies are crucial for managing stroke.
• Atherothrombotic stroke recurrence is reduced by early, continuous antiplatelet therapy.
• Cardioembolic stroke prevention relies on oral anticoagulation.

Purpose of the Study:

• To review the efficacy and safety of antithrombotic and thrombolytic agents in stroke.
• To compare aspirin with other antiplatelet agents for stroke recurrence.
• To evaluate the role of anticoagulation and rt-PA in stroke management.

Main Methods:

• Review of large, randomized clinical trials.
• Comparative analysis of antiplatelet agents.
• Assessment of thrombolytic therapy outcomes.

Main Results:

• Several antiplatelet agents (ticlopidine, clopidogrel, aspirin-dipyridamole) are more effective than aspirin.
• Oral anticoagulation is effective for cardioembolic stroke prevention.
• Recombinant tissue plasminogen activator (rt-PA) improves outcomes in ischemic stroke if given within 3 hours.

Conclusions:

• Antiplatelet agents and anticoagulation are vital for stroke prevention and treatment.
• Early administration of rt-PA is critical for improving outcomes in acute ischemic stroke.
• The risk-benefit profile of rt-PA is acceptable, even in the geriatric population.